Stargardt Disease News and Research

RSS
Stargardt disease, also known as Stargardt macular dystrophy or juvenile macular degeneration, is a condition that involves the retina of the eye. The retina is the layer of the eye which is responsible for sensing light. Most people with Stargardt disease have some loss of vision at a young age, either as a child or an adolescent, although some people may retain good vision until adulthood. It is estimated that about 1 in 10,000 people has Stargardt disease.

Further Reading

Gentle combination of FDA-approved drugs could combat photoreceptor degeneration in mice

Gentle combination of FDA-approved drugs could combat photoreceptor degeneration in mice

Combinations of FDA-approved drugs may prevent vision loss linked to retinal degeneration

Combinations of FDA-approved drugs may prevent vision loss linked to retinal degeneration

Study pinpoints how immune abnormalities in retina may lead to macular degeneration

Study pinpoints how immune abnormalities in retina may lead to macular degeneration

Makindus' MI-100 granted EMA orphan drug designation for treatment of Stargardt's Disease

Makindus' MI-100 granted EMA orphan drug designation for treatment of Stargardt's Disease

Envision Conference 2014 kicks off with presentation of two prestigious awards

Envision Conference 2014 kicks off with presentation of two prestigious awards

ACT announces European phase I clinical trial for Stargardt's disease using retinal pigment epithelial cells

ACT announces European phase I clinical trial for Stargardt's disease using retinal pigment epithelial cells

Lack of very long chain fatty acids does not cause blindness in children with Stargardt type 3

Lack of very long chain fatty acids does not cause blindness in children with Stargardt type 3

Foundation Fighting Blindness grants US$125,000 to Oxford BioMedica for UshStat Phase I/IIa trial

Foundation Fighting Blindness grants US$125,000 to Oxford BioMedica for UshStat Phase I/IIa trial

Otsuka, Acucela commence rebamipide ophthalmic suspension Phase 3 trial in dry eye syndrome

Otsuka, Acucela commence rebamipide ophthalmic suspension Phase 3 trial in dry eye syndrome

ACT treats fourth patient in U.S. clinical trial for Stargardt's Macular Dystrophy

ACT treats fourth patient in U.S. clinical trial for Stargardt's Macular Dystrophy

New data from Acucela’s ACU-4429 Phase 2a trial on advanced dry AMD/geographic atrophy

New data from Acucela’s ACU-4429 Phase 2a trial on advanced dry AMD/geographic atrophy

ACT announces dosing of third patient in dry AMD Phase I/II trial

ACT announces dosing of third patient in dry AMD Phase I/II trial

Experts comment on successful stem cell therapy for blindness

Experts comment on successful stem cell therapy for blindness

Stem cells show promise in treating blindness

Stem cells show promise in treating blindness

Mayo Clinic, Oxford BioMedica collaborate to develop gene therapy for glaucoma

Mayo Clinic, Oxford BioMedica collaborate to develop gene therapy for glaucoma

FDA approves Oxford BioMedica's UshStat IND to treat Usher syndrome type 1B

FDA approves Oxford BioMedica's UshStat IND to treat Usher syndrome type 1B

ACT receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt's Macular Dystrophy

ACT receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt's Macular Dystrophy

New collaboration reinforces Sanofi's translational discovery platform for retinal diseases

New collaboration reinforces Sanofi's translational discovery platform for retinal diseases

Oxford BioMedica reports RetinoStat progress in Phase I study against wet AMD

Oxford BioMedica reports RetinoStat progress in Phase I study against wet AMD